MCID: SPN186
MIFTS: 66

Spinal Cord Injury

Categories: Bone diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Spinal Cord Injury

MalaCards integrated aliases for Spinal Cord Injury:

Name: Spinal Cord Injury 39 77 55 60 17
Spinal Cord Injuries 44

Characteristics:

Orphanet epidemiological data:

60
spinal cord injury
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

ICD10 via Orphanet 35 T09.3
UMLS via Orphanet 75 C0037929
Orphanet 60 ORPHA90058

Summaries for Spinal Cord Injury

MedlinePlus : 44 Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Spinal Cord Injury, also known as spinal cord injuries, is related to brain injury and traumatic brain injury. An important gene associated with Spinal Cord Injury is RTN4IP1 (Reticulon 4 Interacting Protein 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Pregabalin and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

NINDS : 55 A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy axons -- extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis

Wikipedia : 77 A spinal cord injury (SCI) is damage to the spinal cord that causes temporary or permanent changes in... more...

Related Diseases for Spinal Cord Injury

Diseases related to Spinal Cord Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 437)
# Related Disease Score Top Affiliating Genes
1 brain injury 31.1 BDNF CASP3 GFAP IL6
2 traumatic brain injury 30.8 AQP4 BDNF CASP3 GFAP IL6
3 arteries, anomalies of 30.3 IL6 MMP9 TNF
4 myelitis 30.3 AQP4 IL6 TNF
5 prostatitis 30.3 IL6 TGFB1 TNF
6 multiple sclerosis 30.1 AQP4 BDNF GFAP IL6 MMP9 NOS2
7 spinal cord disease 30.1 AQP4 GDNF IL6 TNF
8 disease of mental health 30.1 BDNF IL6 PDYN
9 end stage renal failure 30.0 IL6 TGFB1 TNF
10 transverse myelitis 29.8 AQP4 IL6 MMP9 TNF
11 peripheral nervous system disease 29.6 AQP4 IL6 TNF
12 liver disease 29.5 CASP3 IL6 TGFB1 TNF
13 vascular disease 29.5 IL6 MAPK1 MMP9 NOS2 TNF
14 amyotrophic lateral sclerosis 1 29.2 BDNF CASP3 GDNF GFAP NGFR NOS1
15 alzheimer disease 28.8 BDNF CASP3 GDNF GFAP MAPK1 NGFR
16 respiratory failure 11.7
17 spasticity 11.6
18 central cord syndrome 11.6
19 paraplegia 11.5
20 neurogenic bowel 11.5
21 acute cystitis 11.5
22 syringomyelia 11.5
23 spinal shock 11.4
24 myoclonus 11.4
25 tethered cord syndrome 11.4
26 swallowing disorders 11.4
27 tethered spinal cord syndrome 11.1
28 central cervical cord syndrome 11.1
29 neurogenic bladder 10.7
30 decubitus ulcer 10.7
31 depression 10.6
32 pain - chronic 10.6
33 quadriplegia 10.5
34 impotence 10.5
35 bacteriuria 10.5
36 detrusor sphincter dyssynergia 10.5
37 pure autonomic failure 10.5
38 infertility 10.4
39 scorpion envenomation 10.4 IL6 TNF
40 anxiety 10.4
41 thrombosis 10.4
42 autoimmune inner ear disease 10.4 MMP9 TNF
43 sexual disorder 10.4
44 leukomalacia 10.4 IL6 TNF
45 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL6 TNF
46 cerebral artery occlusion 10.3 BDNF GDNF TNF
47 neural tube defects 10.3
48 aging 10.3
49 male infertility 10.3
50 hypoxia 10.3

Graphical network of the top 20 diseases related to Spinal Cord Injury:



Diseases related to Spinal Cord Injury

Symptoms & Phenotypes for Spinal Cord Injury

GenomeRNAi Phenotypes related to Spinal Cord Injury according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CASP3 GDNF NGFR NOS2 TGFB1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CASP3 GDNF MAPK1 NGFR NOS2 TGFB1

MGI Mouse Phenotypes related to Spinal Cord Injury:

47 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.51 AQP4 BDNF CASP3 GDNF GFAP IL6
2 homeostasis/metabolism MP:0005376 10.44 AQP4 ARG1 BDNF CASP3 GFAP IL6
3 digestive/alimentary MP:0005381 10.42 AQP4 BDNF CASP3 GDNF GFAP IL6
4 cellular MP:0005384 10.4 BDNF CASP3 GDNF GFAP IL6 MAPK1
5 growth/size/body region MP:0005378 10.4 AQP4 BDNF CASP3 GDNF GFAP IL6
6 cardiovascular system MP:0005385 10.38 AQP4 CASP3 GDNF GFAP IL6 MAPK1
7 nervous system MP:0003631 10.36 AQP4 ARG1 BDNF CASP3 GDNF GFAP
8 mortality/aging MP:0010768 10.35 AQP4 ARG1 BDNF CASP3 GDNF GFAP
9 immune system MP:0005387 10.34 AQP4 ARG1 CASP3 GDNF GFAP IL6
10 hematopoietic system MP:0005397 10.33 AQP4 ARG1 CASP3 GDNF IL6 MAPK1
11 endocrine/exocrine gland MP:0005379 10.27 AQP4 BDNF CASP3 GDNF IL6 MAPK1
12 integument MP:0010771 10.21 BDNF CASP3 IL6 MAPK1 MMP9 NGFR
13 muscle MP:0005369 10.2 CASP3 GDNF GFAP IL6 MAPK1 MMP9
14 adipose tissue MP:0005375 10.16 IL6 NGFR NOS1 NOS2 PDYN TGFB1
15 craniofacial MP:0005382 10.13 BDNF CASP3 MAPK1 NGFR NOS2 TGFB1
16 liver/biliary system MP:0005370 10.1 ARG1 IL6 MAPK1 NGFR NOS1 NOS2
17 renal/urinary system MP:0005367 10.02 AQP4 CASP3 GDNF IL6 MMP9 NGFR
18 reproductive system MP:0005389 10.02 BDNF CASP3 GDNF IL6 MAPK1 MMP9
19 respiratory system MP:0005388 10 AQP4 BDNF CASP3 IL6 MAPK1 MMP9
20 no phenotypic analysis MP:0003012 9.95 AQP4 BDNF CASP3 NOS1 PDYN RTN4R
21 skeleton MP:0005390 9.85 CASP3 IL6 MAPK1 MMP9 NGFR NOS1
22 vision/eye MP:0005391 9.4 AQP4 BDNF CASP3 GFAP IL6 MAPK1
23 taste/olfaction MP:0005394 9.26 BDNF CASP3 MAPK1 NGFR

Drugs & Therapeutics for Spinal Cord Injury

Drugs for Spinal Cord Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 444)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 148553-50-8 5486971
2
tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1401-55-4
3
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
4
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
5
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
6
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5633-20-5 4634
7
Baclofen Approved Phase 4,Phase 2,Not Applicable 1134-47-0 2284
8
Dopamine Approved Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
9
Tadalafil Approved, Investigational Phase 4,Phase 3 171596-29-5 110635
10
Amitriptyline Approved Phase 4 50-48-6 2160
11
Perphenazine Approved Phase 4 58-39-9 4748
12
Teriparatide Approved, Investigational Phase 4,Phase 2 52232-67-4 16133850
13
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
14
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
15
Norepinephrine Approved Phase 4,Phase 2,Not Applicable 51-41-2 439260
16
Sodium Citrate Approved, Investigational Phase 4,Not Applicable 68-04-2
17
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
18
Neostigmine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-99-4 4456
19
Darifenacin Approved, Investigational Phase 4,Phase 2 133099-04-4 444031
20
Oxcarbazepine Approved Phase 4 28721-07-5 34312
21
Midodrine Approved Phase 4,Phase 3,Phase 2 133163-28-7, 42794-76-3 4195
22
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
23
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 93-14-1 3516
24
Dextromethorphan Approved Phase 4,Phase 2 125-71-3 5362449 5360696
25
Droxidopa Approved, Investigational Phase 4,Phase 1 23651-95-8 443940
26
Cycloserine Approved Phase 4,Early Phase 1 68-41-7 401 6234
27
Denosumab Approved Phase 4 615258-40-7
28
Trazodone Approved, Investigational Phase 4,Phase 2 19794-93-5 5533
29
Glucagon Approved Phase 4 16941-32-5
30
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
31
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
32
Vancomycin Approved Phase 4 1404-90-6 441141 14969
33
Fidaxomicin Approved Phase 4 873857-62-6
34
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
35
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
36
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
37
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
38
Serine Approved, Nutraceutical Phase 4,Phase 2,Phase 3 56-45-1 5951
39
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
40 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
44 calcium channel blockers Phase 4,Phase 3,Not Applicable
45 Anti-Anxiety Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
46 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Anticonvulsants Phase 4,Phase 3,Phase 2,Not Applicable
49 Tranquilizing Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
50 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1143)
# Name Status NCT ID Phase Drugs
1 Exoskeletons for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943669 Phase 4
2 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
3 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
4 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
5 A Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
6 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
7 Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males Completed NCT01067391 Phase 4 tadalafil;placebo
8 Assess Efficacy in Subjects With Traumatic Spinal Cord Injury Completed NCT00667966 Phase 4 Vardenafil (Levitra, BAY 38-9456), 10 mg;Placebo;Vardenafil (Levitra, BAY 38-9456), 20 mg
9 Chronic Pain in Spinal Cord Injury Completed NCT00006428 Phase 4 Amitriptyline
10 Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients Completed NCT01579500 Phase 4 Botulinum toxin type A;normal saline
11 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
12 Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI) Completed NCT00826228 Phase 4 teriparatide
13 Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury Completed NCT00252954 Phase 4 Levetiracetam
14 Pressure Ulcer Healing With Microcyn Completed NCT02001558 Phase 4 Microcyn
15 Project to Improve Symptoms and Mood in People With Spinal Cord Injury Completed NCT00592384 Phase 4 venlafaxine XR;placebo
16 A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction Completed NCT00654082 Phase 4 sildenafil;placebo
17 Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury Completed NCT00286520 Phase 4
18 Zoledronic Acid Administration in Acute Spinal Cord Injury Completed NCT02042872 Phase 4 Zoledronic acid
19 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage Completed NCT00745095 Phase 4 Neostigmine
20 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed NCT00800462 Phase 4 Oxybutynin Cl;Trospium Cl;Darifenacin Hydrogen Bromide (HBr)
21 Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
22 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition Completed NCT00224029 Phase 4 Oxybutynin transdermal system
23 Omega-3 Supplementation for Tetraplegics With Poor Cholesterol Levels Completed NCT01896037 Phase 4
24 Symptom Based Treatment of Neuropathic Pain Completed NCT02180880 Phase 4 Pregabalin and Oxcarbazepine
25 Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections Completed NCT00318591 Phase 4
26 Body Temperature in Persons With Tetraplegia When Exposed to Cold Completed NCT01822535 Phase 4 Midodrine hydrochloride
27 Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia Completed NCT00507546 Phase 4 Ramelteon;Placebo
28 Evaluation of the Nursing C-Spine (Phase IV) Completed NCT01353352 Phase 4
29 C7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain Completed NCT02095197 Phase 4 Triamcinolone 80mg
30 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
31 Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD Recruiting NCT02537899 Phase 4 NeuroAiD
32 Bowel Care and Cardiovascular Function After Spinal Cord Injury Recruiting NCT01567605 Phase 4 Lidocaine lubricant
33 Lower Limb Function After Spinal Cord Injury Recruiting NCT02635893 Phase 4 D-Cycloserine;Placebo
34 Enhancing STDP After Spinal Cord Injury Recruiting NCT02701777 Phase 4 Seromycin;Dextromethorphan;Seromycin Placebo;Dextromethorphan Placebo
35 Denosumab Administration After Spinal Cord Injury Recruiting NCT01983475 Phase 4 Denosumab;Placebo (identical Denosumab volume of normal saline)
36 The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury Recruiting NCT03029442 Phase 4 Denosumab (Prolia)
37 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
38 Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury Recruiting NCT02922894 Phase 4 Trazodone;Placebo
39 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction Recruiting NCT03169582 Phase 4 Avanafil;Sildenafil
40 Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among SCI Recruiting NCT03748290 Phase 4 Pregabalin;Placebo Oral Tablet
41 Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia Recruiting NCT02379156 Phase 4 Midodrine Hydrochloride
42 Nerve Transfer Reconstruction in the Tetraplegic Upper Extremity Recruiting NCT01579604 Phase 4
43 Intrathecal (IT) Baclofen Drug Distribution Recruiting NCT02903823 Phase 4 Baclofen bolus injection
44 Prevention of Bladder Dysfunction in Acute Spinal Cord Injury Active, not recruiting NCT01698138 Phase 4 Onabotulinumtoxin A;Placebo
45 Once Weekly GLP-1 in Persons With Spinal Cord Injury Not yet recruiting NCT03292315 Phase 4 Exenatide 2 MG Injection [Bydureon]
46 Treatment of Chemotherapy-related Hiccups With Baclofen Not yet recruiting NCT03778281 Phase 4 Baclofen;Methoxyclopramide
47 Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury Terminated NCT02355938 Phase 4 Fidaxomicin 200 mg;Placebo;Vancomycin
48 Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured Terminated NCT00869427 Phase 4 vitamin C
49 Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury Withdrawn NCT02970773 Phase 4 Rivaroxaban Oral Tablet
50 Minocycline in Acute Spinal Cord Injury (MASC) Unknown status NCT01828203 Phase 3 Minocycline;Placebo

Search NIH Clinical Center for Spinal Cord Injury

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spinal Cord Injury cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spinal Cord Injury:
Adipose spheroid-derived Schwann cells for the treatment of spinal cord injury
Bone marrow-derived hematopoietic stem cells for spinal cord injury
Cerecellgram-Spine, bone marrow-derived mesenchymal stem cells for treatment of chronic spinal cord injury
GRNOPC1, hESC-derived oligodendrocyte progenitor cells for spinal cord injury
HuCNS-SC�, human central nervous system stem cells for neurological diseases
MultiStem�, bone marrow-derived cells for neurological disorders
NSI-566, spinal cord stem cells for neurological disorders
RNL-Astrostem�, adipose-derived mesenchymal stem cells for treatment of spinal cord injury
Schwann cells for treatment of spinal cord injury
Umbilical cord-derived mesenchymal stem cells for treatment of spinal cord injury
Embryonic/Adult Cultured Cells Related to Spinal Cord Injury:
Schwann-like cells PMIDs: 20083105
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19364066
Bone marrow-derived mesenchymal stem cells
Oligodendrocyte progenitor-like cells PMIDs: 17996308 17253955
Human neural stem cells (HuCNS-SC�) PMIDs: 16610769
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Fetal spinal cord stem cells (NSI-566) PMIDs: 22415942 19326469
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080 22017805
Schwann cells PMIDs: 16629629 23098734 23186720
Schwann cells PMIDs: 16629629 23098734 23186720
Umbilical cord-derived mesenchymal stem cells PMIDs: 23942181

Genetic Tests for Spinal Cord Injury

Anatomical Context for Spinal Cord Injury

MalaCards organs/tissues related to Spinal Cord Injury:

42
Spinal Cord, Bone, Brain, Testes, Bone Marrow, Colon, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spinal Cord Injury:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
4 Peripheral Nervous System Peripheral Nerve Domain Myelinating Schwann Cells Potential therapeutic candidate
5 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
6 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
7 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
8 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Spinal Cord Injury

Articles related to Spinal Cord Injury:

(show top 50) (show all 7171)
# Title Authors Year
1
An epidemiological study of traumatic spinal cord injuries in the fastest aging area in Japan. ( 30733575 )
2019
2
Understanding the Changing Health Care Needs of Individuals Aging With Spinal Cord Injury. ( 30774290 )
2019
3
Spinal cord injury by clip-compression induces anxiety and depression-like behaviours in female rats: The role of the inflammatory response. ( 30659938 )
2019
4
Determining Best Practices for Management of Bacteriuria in Spinal Cord Injury: Protocol for a Mixed-Methods Study. ( 30762584 )
2019
5
Cognitive, Emotional, and Physical Functioning as Predictors of Paid Employment in People With Stroke, Traumatic Brain Injury, and Spinal Cord Injury. ( 30915962 )
2019
6
Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. ( 30497965 )
2019
7
Anti-muscarinic drugs increase rectal compliance and exacerbate constipation in chronic spinal cord injury : Anti-muscarinic drug effect on neurogenic bowel. ( 30804425 )
2019
8
Anal Adrenergic for Fecal Incontinence (in Spinal Cord Injury). ( 30640827 )
2019
9
Hyperglycemia aggravates spinal cord injury through endoplasmic reticulum stress mediated neuronal apoptosis, gliosis and activation. ( 30784940 )
2019
10
Minocycline impedes mitochondrial-dependent cell death and stabilizes expression of hypoxia inducible factor-1α in spinal cord injury. ( 30899301 )
2019
11
Investigating neurogenic bowel in experimental spinal cord injury: where to begin? ( 30531001 )
2019
12
Identifying and Classifying Quality of Life Tools for Assessing Neurogenic Bowel Dysfunction After Spinal Cord Injury. ( 30774286 )
2019
13
Predicting osteoporosis medication receipt in Veterans with a spinal cord injury: A retrospective cohort study. ( 30888309 )
2019
14
Intermittent injection of Methylprednisolone Sodium Succinate in the treatment of Cervical Spinal Cord injury complicated with incomplete paraplegia. ( 30881412 )
2019
15
Repeated anodal trans-spinal direct current stimulation results in long-term reduction of spasticity in mice with spinal cord injury. ( 30689208 )
2019
16
Effect of electrical stimulation on muscle atrophy and spasticity in patients with spinal cord injury - a systematic review with meta-analysis. ( 30696926 )
2019
17
Non-invasive spinal direct current simulation for spasticity therapy following spinal cord injury: mechanistic insights contributing to long-term treatment effects. ( 30820947 )
2019
18
Early Intravenous Infusion of Mesenchymal Stromal Cells Exerts a Tissue Source Age-Dependent Beneficial Effect on Neurovascular Integrity and Neurobehavioral Recovery After Traumatic Cervical Spinal Cord Injury. ( 30912623 )
2019
19
Increased Lower Limb Loading During Sit-to-Stand is Important for the Potential for Walking Progression in Ambulatory Individuals with Spinal Cord Injury. ( 30914897 )
2019
20
Bone Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Recovery Following Spinal Cord Injury via Improvement of the Integrity of the Blood-Spinal Cord Barrier. ( 30914918 )
2019
21
Curcumin Can Improve Spinal Cord Injury by Inhibiting TGF-β-SOX9 Signaling Pathway. ( 30915623 )
2019
22
MiR-92b-5p inhibitor suppresses IL-18 mediated inflammatory amplification after spinal cord injury via IL-18BP up-regulation. ( 30915731 )
2019
23
Social participation and personal autonomy of individuals with spinal cord injury. ( 30916291 )
2019
24
Reducing alpha-synuclein in spinal cord injury: A new strategy of treatment. ( 30916814 )
2019
25
Combinatorial Tissue Engineering Partially Restores Function after Spinal Cord Injury. ( 30808065 )
2019
26
White Matter Microstructure Alterations in Patients With Spinal Cord Injury Assessed by Diffusion Tensor Imaging. ( 30809136 )
2019
27
BRD4 inhibition attenuates inflammatory response in microglia and facilitates recovery after spinal cord injury in rats. ( 30809946 )
2019
28
Short-term effects of core stability training on the balance and ambulation function of individuals with chronic spinal cord injury: a pilot randomized controlled trial. ( 30809995 )
2019
29
Simvastatin and Simvastatin-Ezetimibe Improve the Neurological Function and Attenuate the Endothelial Inflammatory Response after Spinal Cord Injury in Rat. ( 30814085 )
2019
30
Influence of training protocols on text input speed on a computer in individuals with cervical spinal cord injury: a randomised controlled trial. ( 30814669 )
2019
31
Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial. ( 30814670 )
2019
32
Motor Recovery after Transplantation of Bone Marrow Mesenchymal Stem Cells in Rat Models of Spinal Cord Injury. ( 30814821 )
2019
33
The impact of early (<24h) surgical decompression on neurological recovery in thoracic spinal cord injury: a meta-analysis. ( 30816058 )
2019
34
SIRT1 inhibits apoptosis in in vivo and in vitro models of spinal cord injury via microRNA-494. ( 30816451 )
2019
35
Construction and analysis of a spinal cord injury competitive endogenous RNA network based on the expression data of long noncoding, micro‑ and messenger RNAs. ( 30816457 )
2019
36
Caloric intake relative to total daily energy expenditure using a spinal cord injury-specific correction factor: an analysis by level of injury. ( 30817378 )
2019
37
Interrater and intrarater reliability of ventilatory thresholds determined in individuals with spinal cord injury. ( 30820032 )
2019
38
Upregulation of miRNA-223-3p ameliorates RIP3-mediated necroptosis and inflammatory responses via targeting RIP3 after spinal cord injury. ( 30821011 )
2019
39
Clustering analysis to identify key genes associated with motor neuron excitability following spinal cord injury. ( 30821549 )
2019
40
Three-dimensional changes in cervical spinal cord microvasculature during the chronic phase of hemi-contusion spinal cord injury in rats. ( 30822573 )
2019
41
Application of Hepatocyte Growth Factor for Acute Spinal Cord Injury: The Road from Basic Studies to Human Treatment. ( 30823442 )
2019
42
Development and feasibility testing of an online virtual reality platform for delivering therapeutic group singing interventions for people living with spinal cord injury. ( 30823854 )
2019
43
Neuroprotective Effects of Combined Treatment with Minocycline and Olfactory Ensheathing Cells Transplantation against Inflammation and Oxidative Stress after Spinal Cord Injury. ( 30825296 )
2019
44
MicroRNA biomarkers in cerebrospinal fluid and serum reflect injury severity in human acute traumatic spinal cord injury. ( 30827169 )
2019
45
Comprehensive therapeutics targeting the corticospinal tract following spinal cord injury. ( 30829009 )
2019
46
Interprofessional Collaboration and Peer Mentors for Bowel Education in Spinal Cord Injury: A Case Consultation. ( 30830010 )
2019
47
Factors related to hospital readmissions in people with spinal cord injury in South Africa. ( 30834861 )
2019
48
Introduction. Acute spinal cord injury. ( 30835672 )
2019
49
Efficacy of riluzole in the treatment of spinal cord injury: a systematic review of the literature. ( 30835675 )
2019
50
Value of aggressive surgical and intensive care unit in elderly patients with traumatic spinal cord injury. ( 30835676 )
2019

Variations for Spinal Cord Injury

Expression for Spinal Cord Injury

Search GEO for disease gene expression data for Spinal Cord Injury.

Pathways for Spinal Cord Injury

Pathways related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 ARG1 CASP3 GDNF IL6 MAPK1 MMP9
2
Show member pathways
13.59 BDNF CASP3 GDNF IL6 MAPK1 NGFR
3
Show member pathways
13.36 CASP3 GDNF IL6 MAPK1 MMP9 NOS2
4
Show member pathways
13.3 AQP4 BDNF CASP3 IL6 MAPK1 TGFB1
5
Show member pathways
13.29 BDNF CASP3 IL6 MAPK1 NGFR PLA2G2A
6
Show member pathways
13.08 BDNF IL6 MAPK1 NGFR PLA2G2A TGFB1
7
Show member pathways
13.01 BDNF CASP3 IL6 MAPK1 NGFR TNF
8
Show member pathways
12.99 CASP3 IL6 MAPK1 MMP9 TGFB1 TNF
9
Show member pathways
12.98 CASP3 IL6 MAPK1 MMP9 NGFR TNF
10
Show member pathways
12.89 CASP3 GDNF IL6 MAPK1 TGFB1 TNF
11 12.84 CASP3 IL6 MAPK1 MMP9 NOS2 TGFB1
12 12.76 BDNF CASP3 MAPK1 NGFR TGFB1 TNF
13
Show member pathways
12.73 BDNF IL6 NGFR TGFB1 TNF
14
Show member pathways
12.6 IL6 MAPK1 NOS1 NOS2 TNF
15
Show member pathways
12.51 CASP3 MAPK1 NOS1 PDYN TNF
16
Show member pathways
12.44 IL6 MAPK1 TGFB1 TNF
17
Show member pathways
12.34 CASP3 IL6 MAPK1 MMP9 TNF
18
Show member pathways
12.33 IL6 MAPK1 NOS2 TNF
19 12.31 CASP3 MAPK1 MMP9 TGFB1 TNF
20
Show member pathways
12.28 BDNF IL6 NGFR TGFB1 TNF
21
Show member pathways
12.26 CASP3 MAPK1 NOS2 TGFB1 TNF
22
Show member pathways
12.24 IL6 MAPK1 NOS2 TNF
23
Show member pathways
12.18 MAPK1 PLA2G2A TGFB1 TNF
24 12.15 AQP4 BDNF CASP3 IL6 TNF
25 12.13 BDNF CASP3 MAPK1 NGFR
26 12.13 CASP3 IL6 MAPK1 NOS2 TGFB1 TNF
27
Show member pathways
12.1 BDNF IL6 MAPK1 NGFR TGFB1
28 11.93 IL6 MMP9 NOS2 TGFB1 TNF
29 11.92 IL6 MAPK1 NOS2
30 11.92 CASP3 IL6 MAPK1 MMP9 NOS2 TGFB1
31 11.9 CASP3 IL6 MAPK1 MMP9 TNF
32 11.88 CASP3 MAPK1 TGFB1
33 11.87 IL6 TGFB1 TNF
34 11.86 MAPK1 TGFB1 TNF
35 11.84 IL6 MAPK1 NOS2
36 11.83 CASP3 IL6 MAPK1 TGFB1 TNF
37 11.8 BDNF GDNF GFAP
38 11.77 IL6 TGFB1 TNF
39 11.72 ARG1 CASP3 IL6 NOS2 TGFB1 TNF
40 11.71 CASP3 IL6 MMP9
41 11.7 CASP3 MAPK1 MMP9 NOS2
42
Show member pathways
11.7 BDNF CASP3 NGFR RTN4R
43
Show member pathways
11.67 BDNF MAPK1 NGFR
44 11.66 IL6 MMP9 TGFB1 TNF
45 11.66 AQP4 ARG1 BDNF CASP3 GDNF GFAP
46 11.65 CASP3 MMP9 PLA2G2A
47 11.65 CASP3 IL6 MAPK1 NOS2 TNF
48
Show member pathways
11.64 ARG1 NOS1 NOS2
49 11.62 CASP3 IL6 TNF
50 11.57 ARG1 IL6 MAPK1 NOS2

GO Terms for Spinal Cord Injury

Cellular components related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 ARG1 BDNF IL6 KLK8 MMP9 PLA2G2A
2 membrane raft GO:0045121 9.46 CASP3 NOS1 RTN4R TNF
3 extracellular region GO:0005576 9.4 ARG1 BDNF GDNF IL6 KLK8 MAPK1
4 neuronal cell body GO:0043025 9.35 ARG1 CASP3 PDYN RTN4R TGFB1

Biological processes related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.91 GDNF MAPK1 TGFB1 TNF
2 regulation of signaling receptor activity GO:0010469 9.91 BDNF GDNF IL6 PDYN TGFB1 TNF
3 response to hypoxia GO:0001666 9.84 CASP3 NOS1 NOS2 TGFB1
4 defense response to Gram-positive bacterium GO:0050830 9.83 IL6 PLA2G2A TNF
5 cellular response to lipopolysaccharide GO:0071222 9.83 ARG1 IL6 NOS2 TNF
6 response to organic substance GO:0010033 9.82 CASP3 TGFB1 TNF
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.81 CASP3 NGFR TNF
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 IL6 TGFB1 TNF
9 positive regulation of apoptotic process GO:0043065 9.8 CASP3 IL6 MMP9 NGFR TGFB1 TNF
10 cellular response to organic cyclic compound GO:0071407 9.77 CASP3 TGFB1 TNF
11 response to glucocorticoid GO:0051384 9.77 CASP3 IL6 TNF
12 axon guidance GO:0007411 9.74 BDNF GDNF MAPK1
13 negative regulation of fat cell differentiation GO:0045599 9.69 IL6 TGFB1 TNF
14 membrane protein intracellular domain proteolysis GO:0031293 9.65 NGFR TGFB1
15 lipopolysaccharide-mediated signaling pathway GO:0031663 9.65 MAPK1 TGFB1 TNF
16 response to lipopolysaccharide GO:0032496 9.65 ARG1 CASP3 MAPK1 NOS1 NOS2
17 nitric oxide biosynthetic process GO:0006809 9.64 NOS1 NOS2
18 negative regulation of activated T cell proliferation GO:0046007 9.63 ARG1 CASP3
19 cytokine-mediated signaling pathway GO:0019221 9.63 CASP3 IL6 MMP9 NOS2 TGFB1 TNF
20 negative regulation of axon regeneration GO:0048681 9.62 KLK8 RTN4R
21 positive regulation of guanylate cyclase activity GO:0031284 9.62 NOS1 NOS2
22 negative regulation of lipid storage GO:0010888 9.61 IL6 TNF
23 Bergmann glial cell differentiation GO:0060020 9.58 GFAP MAPK1
24 negative regulation of neuron projection development GO:0010977 9.58 GFAP RTN4R
25 neurotrophin TRK receptor signaling pathway GO:0048011 9.58 BDNF CASP3 NGFR
26 positive regulation of receptor binding GO:1900122 9.56 BDNF MMP9
27 positive regulation of neuroinflammatory response GO:0150078 9.55 IL6 TNF
28 positive regulation of glial cell proliferation GO:0060252 9.54 GFAP IL6 TNF
29 peptidyl-cysteine S-nitrosylation GO:0018119 9.49 NOS1 NOS2
30 positive regulation of mononuclear cell migration GO:0071677 9.46 TGFB1 TNF
31 arginine catabolic process GO:0006527 9.13 ARG1 NOS1 NOS2
32 response to wounding GO:0009611 9.02 ARG1 CASP3 GFAP KLK8 TGFB1
33 negative regulation of apoptotic process GO:0043066 10.06 CASP3 GDNF IL6 MMP9 NGFR

Molecular functions related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 BDNF GDNF IL6 TGFB1
2 arginine binding GO:0034618 9.32 NOS1 NOS2
3 NADPH-hemoprotein reductase activity GO:0003958 9.26 NOS1 NOS2
4 tetrahydrobiopterin binding GO:0034617 8.96 NOS1 NOS2
5 nitric-oxide synthase activity GO:0004517 8.62 NOS1 NOS2

Sources for Spinal Cord Injury

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....